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ABSTRACT
Introduction Air pollution is a hot topic and is known 
to cause multiple health issues. Especially pregnant 
women seem to be vulnerable to environmental issues. 
There are data suggesting that exposure contributes to 
hypertensive disorders. This study aims to evaluate the 
effects of exposure to particulate matter (PM) and outdoor 
air pollutants on the clinical pregnancy outcome for mother 
and child and to determine which biochemical changes in 
maternal, placental and cord blood best explain this effect.
Methods and analysis This study is a prospective 
cohort study. We aim to recruit 200 pregnant women. The 
outcome measurements will include maternal parameters, 
labour parameters and neonatal parameters. Multiple 
samples will be analysed such as maternal urine samples 
(8-oxo-deoxyguanosine), maternal blood samples (routine 
blood sampling, biomarkers of pre-eclampsia and 
transcript markers), maternal hair samples, neonatal blood 
samples (transcript markers) combined with extensive 
questionnaires.
Ethics and dissemination We obtain informed consent 
from each participant prior to enrolment in the study. The 
study has received approval by the Ethical Committee of 
the Antwerp University Hospital (14/40/411). IPANEMA is 
the first prospective study to assess the impact of PM on 
mothers and babies in Antwerp, Belgium. Findings from 
this study will contribute to improve knowledge on the 
impact of exposure to air pollution on mothers and babies 
and will also define biomarkers as predictors for pregnant 
women at risk.
Trial registration  ClinicalTrials. gov: 14/40/411. 
Registered 22-10-2015. 
InTRoduCTIon
An emerging body of evidence indicates that 
there is an association between air pollution 
exposure in pregnancy and adverse pregnancy 
outcomes.1 2 Most studies have estimated 
personal exposure to air pollution by model-
ling data from outdoor monitoring stations 
and interpolating them to the home address 
of the study participants. The exposure data 
are averaged over different time periods and 
in general time spent in traffic or exposure at 
the workplace or indoors are not taken into 
account.
Particulate matter (PM) is an important 
component of outdoor air pollution. PM has 
different sizes, but especially fine PM, with 
an aerodynamic diameter less than 2.5 µm 
(PM2.5) is of great interest, because of its 
small size, large specific surface area and long 
residence in air, and thus is more likely to 
adsorb harmful substances. PM2.5 consists of a 
mixture of solid and liquid particles, emitted 
from a variety of sources. Because of its size it 
can penetrate in airways until the alveoli from 
where the particles or the absorbed pollutants 
may be translocated into the bloodstream.3
A significant positive association between 
exposure to fine PM during the third trimester 
and pre-eclampsia has been observed in a 
study by Dadvand et al among over 8000 preg-
nant women in Barcelona, Spain.2
Exposure to local traffic-generated air 
pollution during pregnancy is also known to 
increase the risk of pre-eclampsia and preterm 
birth.4 Proximity to major roads is associated 
with an increased risk of pre-eclampsia, but 
not with a higher risk of gestational diabetes, 
placental abruption or placenta praevia.5
Strengths and limitations of this study
 ► First prospective study to assess the impact 
of particulate matter on mothers and babies in 
Antwerp, Belgium.
 ► Large questionnaires to minimalise bias from 
multiple factors.
 ► Only eligible for Dutch speaking women, which gives 
a bias.
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Hypertensive disorders of pregnancy affect about 10% 
of all pregnant women. They are an important cause 
of severe morbidity and even mortality.6 Pre-eclampsia 
complicates 2%–8% of pregnancies and is a major contrib-
utor to maternal and neonatal mortality worldwide.7
Pre-eclampsia is generally defined as de novo hyper-
tension occurring after 20 weeks of pregnancy (with 
systolic blood pressure ≥140 mm Hg and/or diastolic 
blood pressure ≥90 mm Hg) and proteinuria (≥300 mg in 
24 hours).6–8
The cause of pre-eclampsia still remains largely 
unknown, but a disturbed placental function early in 
pregnancy has been suggested as a specific underlying 
mechanism. In normal pregnancy the uteroplacental 
arteries undergo a series of pregnancy-related changes in 
the first 20 weeks. Invasive trophoblasts replace endothe-
lial cells and smooth muscle cells in the media, causing 
the arteries to lose elasticity and to dilate to wide tubes, 
without the ability to contract effectively. They also lose 
their vasomotor control. This mechanism occurs in order 
to guarantee maternal blood supply to the placenta: the 
loss of maternal blood flow resistance and the increase 
of uteroplacental perfusion meet the requirements of 
the fetus.9 In addition, circulating antiangiogenic factors 
may play a role in the pathogenesis. The transmem-
brane protein vascular endothelial growth factor (VEGF) 
receptor fms-like tyrosine kinase 1 (Flt-1) binds with high 
affinity to VEGF and to placental growth factor (PlGF).10 
Flt-1 is involved in normal angiogenesis. Soluble Flt-1 
(sFlt-1) is a variant of Flt-1 that lacks a transmembrane 
protein, and is a naturally occurring antagonist of VEGF 
and PlGF. Production of sFlt-1 appears to be expressed by 
endothelial cells and trophoblasts in response to reduced 
oxygen tensions.11 12 In developing pre-eclamptic placenta 
the normal process of remodelling of the uterine spiral 
arteries is impaired, resulting in reduced perfusion, 
increased oxidative stress and inflammation.12
Although there are yet no validated biomarkers that 
allow to identify women at risk for pre-eclampsia, levels 
of angiogenic and antiangiogenic factors are altered in 
women with pre-eclampsia. Levels of sFlt-1 are elevated 
and levels of PlGF are decreased, even before clinical 
symptoms of disease were overt.13 14The ratio of sFlt-1/
PlGF is a promising set of biochemical markers for 
prediction of pre-eclampsia. There is a pathogenic 
difference between early pre-eclampsia (onset of disease 
before 32–34 weeks of pregnancy) and late pre-eclampsia 
(onset of disease after 32–34 weeks of pregnancy). Early 
pre-eclampsia is characterised by a significant placental 
dysfunction, leading to a high risk of intrauterine growth 
restriction. In late pre-eclampsia there is more evidence 
of pre-existing maternal inflammation and/or cardiovas-
cular maladaptation.7 15 The distinction is not always that 
clear, and is under debate.
Cystatin C, a protease inhibitor, is also increased in 
pre-eclamptic women. Cystatin C can be used as an 
endogenous marker for renal function, synthesised by 
all nucleated cells, at a constant rate and exclusively 
eliminated by glomerular filtration.16 Saleh et al found 
that levels of cystatin C were significantly higher in the 
second trimester of pregnancy in women who developed 
pre-eclampsia.17 Angiogenesis-related and stress-related 
pathways may underlie the vascular effects of PM2.5 expo-
sure during pregnancy.10 18 19 Endothelin-1 is an estab-
lished biomarker of endothelium dysfunction.20 Nuclear 
factor of activated T cells (NFAT) contributes to diverse 
functions and was identified as a critical component of 
VEGF-induced angiogenesis.21
Higher exposure to PM2.5 and O3 during the first 
trimester are associated with pre-eclampsia, gestational 
hypertension and preterm delivery.22
We hypothesise that exposure to PM2.5 in the first 
trimester of pregnancy interferes with the maternal 
vascular remodelling process and that impaired remod-
elling between 9 weeks and 18 weeks results in reduced 
placental perfusion and oxidative stress.23
In 2011 WHO stated in a report that supplementa-
tion of calcium during pregnancy for women at high 
risk of developing pre-eclampsia is recommended.6 
They also state that low-dose acetylsalicylic acid (75 mg/
day) is recommended in the same population. A recent 
study by Souza et al24 confirmed that supplementation 
with 100 mg aspirin plus 2 g calcium when started after 
20 weeks of gestational age reduced the rate of super-
imposed pre-eclampsia and intrauterine growth restric-
tion in women with chronic hypertension and abnormal 
second-trimester uterine artery Doppler.24 If this study 
can predict which women are at risk for hypertensive 
disorders during pregnancy or pre-eclampsia, supple-
mentation of aspirin and calcium can be started in order 
to reduce perinatal risks.
objectives and aims of the IPAnEMA Study
This study aims to evaluate the effects of exposure to 
PM and outdoor air pollutants on the clinical pregnancy 
outcome for mother and child and to determine which 
biochemical changes in maternal, placental and cord 
blood best explain this effect.
 ► Objective 1: Correlate estimated personal PM2.5 expo-
sures to angiogenesis-related markers for hyperten-
sive disorders in pregnant woman.
 ► Objective 2: Gain more insight in the pathophysiology 
behind cardiovascular effects of air pollution during 
pregnancy, plausible underlying molecular pathways 
will be assessed, for example, stress-related and angio-
genesis-related pathways.
METhodS And AnAlySIS
Study design and setting
The IPANEMA Study is a regional prospective cohort 
study, recruiting pregnant women in the Antwerp region 
in Belgium.
Data are collected during pregnancy and at delivery, 
as well as immediately postpartum. Blood samples, hair 
samples and anthropometric measurements are obtained. 
Self-administered questionnaires are completed at 
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different time frames in pregnancy, in relation to sample 
taking (see figure 1).
Study sample
Study cohort
Pregnant women are recruited within the network of 
Antwerp University. The leading centre will be University 
Hospital Antwerp, a tertiary centre with a maternal inten-
sive care unit and a neonatal intensive care unit and 1000 
deliveries a year.
The aim is to enrol 200 pregnant women over a 3 -year 
recruitment period. An increase of 2% of pregnant 
women who develop pre-eclampsia or hypertensive disor-
ders can be considered clinically relevant.
Diagnosis of pre-eclampsia (onset of a new episode of 
hypertension during pregnancy (with persistent diastolic 
blood pressure >90 mm Hg) with the occurrence of 
substantial proteinuria (>0.3 g/24 hours)) and hyperten-
sive disorders are made using WHO guidelines.6
Eligibility criteria
The inclusion criteria are (see figure 2)
 ► A singleton pregnancy
 ► More than 12 weeks of gestational age
 ► Delivery planned in a hospital within the network of 
Antwerp University
 ► Dutch speaking
The exclusion criteria are:
 ► Multiple pregnancy
 ► Planned home delivery or planned delivery in another 
hospital
Power calculation and statistical analyses
The incidence of pre-eclampsia in pregnancy is approxi-
mately 5%. An increase of 2% is of interest. A doubling in 
incidence is therefore clinically relevant. With a sample 
size of 200 subjects, a doubling from 5% to 10% can be 
detected with 80% power and 5% significance level.
Data analysis will be done using SPSS V.24.0.
Recruitment started in the summer of 2015 and we aim 
to collect all participants by the end of 2018.
Study visits
Women are recruited by the midwife or obstetrician at 12 
weeks of gestational age, typically at the second routine 
antenatal visit.
Signed informed consent for participating in the study 
is obtained before the start.
Blood collections (maternal and umbilical cord)
Venous blood is drawn around 24 weeks of gestational age 
(table 1).
Umbilical cord blood is taken at the time of birth 
(table 2).
Measurement of molecular pathway and transcript markers For 
analysis of the m(i)RNA profile, whole blood is collected 
in Tempus Blood RNA tubes (Applied Biosystems) and 
stored at −80°C until analysis. Telomere length and DNA 
methylation will be assessed on blood samples collected 
in EDTA tubes, which are stored at −80°C.
In order to gain more insight into pathophysiological 
pathways, relevant biomarkers and transcript markers 
will be analysed. Specific transcript markers will be 
selected that were previously associated with exposure 
Figure 1 Visits and interventions during the IPANEMA 
Study.
Figure 2 Eligibility criteria.
 o
n
 26 July 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-020028 on 9 March 2018. Downloaded from 
4 Van den Eeden L, et al. BMJ Open 2018;8:e020028. doi:10.1136/bmjopen-2017-020028
Open Access 
to PM, intrauterine growth retardation or stress-induced 
and angiogenesis pathways, for example, glucocorticoid 
receptor signalling pathway, NFAT signalling pathway, 
and so on.25
Urine collections
Urine samples are taken by the pregnant women them-
selves, after a minimum of 8 hours fasting (morning 
urine). Samples are handed to the midwife at the ante-
natal visit, and placed in a freezer at −20°C within 12 hours 
of collection. Analysis will be performed at the Flemish 
Institute for Technological Research.
Two urine samples are collected at 20 weeks and at 
30 weeks gestational age; 8-oxo-deoxyguanosine will be 
determined in the samples.
Hair collections
Being incorporated into the growing hair, hair cortisol 
concentrations (HCCs) provide a retrospective reflection 
of integrated cortisol secretion over periods of several 
months.26
Hair samples are drawn by the midwife around 24 
weeks of gestational age and 3 days after delivery. Long 
periods of stress are associated with increased HCCs.26 
Confounding variables are low maternal education, 
season of delivery, smoking during pregnancy and 
obesity.27 Titanium scissors are cleaned with denaturated 
ethanol and the midwife wears disposable gloves in order 
to limit contamination. A lock of hair with a thickness of a 
match (2 mm) and a length of 4 cm will be taken and put 
in an envelope. Analysis will be performed at the Univer-
sity of Southern Denmark.
Statistical analysis
Regression models will be calculated. In particular, birth 
weight will be correlated with PM2.5 values using linear 
regression, pre-eclampsia with blood pressure evolution 
and PM2.5 using logistic regression, birth weight, birth 
weight (dichotomised) and pre-eclampsia with sFlt-1, 
PlGF, cystatin C and PM2.5 using linear and logistic regres-
sions, respectively, and birth weight (dichotomised) 
versus inflammatory parameters using logistic regres-
sion. The effect of the following a priori covariates will be 
analysed: history of pre-eclampsia, diabetes, BMI at start, 
age, smoking, intake of low dose aspirin and pre-existing 
hypertension. These factors will however not be a reason 
for exclusion.
Questionnaires
There are four different questionnaires:
 ► Questionnaire on general habits, socioeconomic factors, life-
style and eating habits
We use a self-designed questionnaire to extensively 
collect information on ethnic origin and education 
level, on employment, income and work environ-
ment, on family history of diseases and chronic disor-
ders, on eating habits, on previous pregnancies and 
other habits (smoking, alcohol consumption).
 ► Questionnaire on lifestyle during previous 3 days
We use a self-designed questionnaire to extensively 
collect information on contact with possible toxic 
factors and on eating pattern of the previous 3 days.
 ► Questionnaire on residential facts
We use a self-designed questionnaire to collect infor-
mation about the exact location of the bedroom 
window and other possible factors influencing 
concentrations of PM.
 ► Questionnaire on stress factors and birth facts
We use a self-designed questionnaire to extensively 
collect information on stress levels during preg-
nancy, on birth facts and on medication during 
pregnancy.
Questionnaires will be taken at different visits (table 3)
Additional clinical information and data about medica-
tion will be obtained by detailed data extraction from the 
hospital records.
outcomes of the study
Diagnosis of cardiovascular disorders
Pre-eclampsia is defined as the onset of a new episode of 
hypertension during pregnancy (with persistent diastolic 
blood pressure >90 mm Hg) with the occurrence of 
substantial proteinuria (>0.3 g/24 hours).
Pregnancy and delivery outcome data
Maternal data that are prospectively collected are: preg-
nancy duration, pre-eclampsia, hypertensive disorders.
Delivery data are: type of labour, type of delivery.
Table 1 Tests on maternal blood sample
Routine blood sampling 
(UZA)
Urea, creatinin, CRP, LDH, AST, 
ALT, uric acid, APTT, PT, fibrinogen, 
D-dimers, glucose, erythrocytes/
haematocrit, haemoglobin, 
thrombocytes, leucocytes, ferritin, 
toxoplasmosa (IgG and IgM),
Cytomegalovirus (IgG and IgM), 
herpes simplex IgG, Varicella 
zoster IgG, rubella IgG, parvovirus 
(IgG and IgM), Syphilis (RPR and 
TPHA), Indirect Coomb's test
Biomarkers of pre-
eclampsia
sFlt-1, PlGF, cystatin C, endothelin
Molecular pathway and 
transcript markers
m(i)RNA expression, telomere 
length, DNA methylation
ALT, alanine transaminase; APTT, activated partial thromboplastin 
time; AST, aspartate aminotransferase; CRP, C-reactive 
protein; LDH, lactate dehydrogenase; PlGF, placental growth 
factor; PT, prothrombin time; RPR, rapid plasma reagin; sFlt-1, 
soluble fms-like tyrosine kinase 1; TPHA, Treponema pallidum 
haemagglutination; UZA, University Hospital Antwerp. 
Table 2 Tests on umbilical blood sample
Transcript markers m(i)RNA expression, telomere length, 
DNA methylation
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Neonatal data are: birth weight, preterm delivery, Apgar 
Scores at 1 min, 5 min and 10 min, congenital anomalies, 
and so on.
Other study measurements
Measurement of sFlt-1, PlGF and cystatin C
Blood samples taken at the study visit around 24 weeks of 
gestational age for the analyses of sFlt-1, PlGF and cystatin 
C are collected, processed and aliquoted within 24 hours 
of collection. The serum samples are stored at −80°C 
until analysis at Algemeen Medisch Laboratorium. sFlt-1 
and PlGF will be determined using an electrochemilumi-
nescence-based sandwich immunoassay on Cobas e 411 
(Roche Diagnostics, Mannheim, Germany).28 29 Cystatin 
C will be determined using a particle-enhanced immu-
nonephelometric assay (N Latex cystatin C, Siemens 
Healthcare Diagnostics, Marburg, Germany) by use of a 
BN II nephelometer (Siemens Healthcare Diagnostics). 
This assay has a calibration traceable to the first certi-
fied reference material for cystatin C in human serum 
(ERM-DA471/IFCC).30
dISCuSSIon
IPANEMA is the first prospective study to assess the impact 
of PM on mothers and babies in Antwerp, Belgium.
Exposure to PM is debated on the political scene but 
robust data showing a relationship with hypertensive 
disorders of pregnancy are difficult to find. In Antwerp 
the design of a safe and functional tunnel for the highway 
is now focus of public discussion. Following the Barce-
lona experience a group of people want an urban tunnel 
complex to lower the amount of PM.
IPANEMA would like to create robust data on the 
correct impact of air pollution, in particular on preg-
nant women, a vulnerable population. IPANEMA uses 
prospective data from the beginning of the pregnancy till 
childbirth.
Available studies have been highly biased, probably in 
favour of detecting an effect even if this is minimal, by 
their retrospective nature (missing for example, women 
who left the area before giving birth), not correcting for 
socioeconomic or ethic influences, using very raw and 
approximate models managing up to several square kilo-
metres as identical areas of pollution, not compensating 
for time spent in traffic, at work or in other regions during 
weekends and holidays. Furthermore the discussion on 
the impact of air pollution had been partially taken over 
by politics, without robust data. Data from IPANEMA will 
help to estimate the real individual dose-effect relation 
for pregnant women.
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